Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-09-26

FDA Approved: DARZALEX — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for DARZALEX (daratumumab) submitted by Janssen Biotech, Inc., resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DARZALEX (daratumumab)

Snippet

SUPPL AP for DARZALEX (DARATUMUMAB)